Chatbots are charming – but can they keep a secret?
By DAVID A. CHAUVIN // Much has been made of the surface-level dangers of generative artificial intelligence: It writes like a robot, invents facts and struggles with nuance. These are…
Voices
In product development, take your time and do it right
By BRAD CARLSON // If the history of product development has one universal truth, it’s this: It’s never easy. The most successful products, of course, follow a simple return-on-investment formula:…
Fair-housing groups fight back as HUD cripples funding
By JEFFREY L. REYNOLDS // A million dollars recently flew out the door of Long Island Housing Services, the only nonprofit fair-housing advocacy and enforcement organization serving Nassau and Suffolk…
Patients, providers feel the pain as federal funds vanish
By TERRY LYNAM // Keeping track of the Trump Administration’s head-spinning budget cuts and layoffs has been tough, but one thing is clear: They could have a staggering impact on…
Centuries later, the Town of Islip is always on the move
By TOM MARINER // As I prepare to board a Long Island Rail Road train at Ronkonkoma Station for a quick journey into the city and another hot-button pharmaceutical conference,…
Time to add nuclear back to Long Island’s energy mix
By MICHAEL H. SAHN // Nuclear power is back – and despite its bad history with nuclear power, Long Island needs to consider it as a progressive energy source. In…
Online-search woes multiply as Google dips, AI rises
By DAVID A. CHAUVIN // For nearly two decades, Google has enjoyed an iron grip on the search-engine market – but the rise of artificial intelligence-driven search alternatives, most notably…
Fresh out of ideas, Amazon pulls its latest bait-and-bail
By ZELORY GREGLER // So Amazon has canceled plans for a new Amazon Fresh supermarket in Farmingville, after building out the place and everything. Color me stunned. Actually, don’t –…
Magic pill? No. But Journavx could provide opioid assist
By JEFFREY L. REYNOLDS // People in acute pain might be relieved to know that the U.S. Food and Drug Administration recently approved Journavx, a novel painkiller that aspires to…
In healthcare, better outcomes are to DEI for
By TERRY LYNAM // I’ve been trying to understand why, when and how the issue of diversity, equity and inclusion became such a political lightening rod. Perhaps I was naïve…
A history of compliance with cornerstone LI consultancy
By TOM MARINER // The U.S. Food and Drug Administration regulates 2 million medical devices and a $1.6 trillion pharmaceuticals industry, all with a nod to a longtime Long Island…
From NYC, a golden chance to build an ‘Island of Yes’
By MICHAEL H. SAHN // The New York City Council has approved historic amendments to the city’s Zoning Resolution – a game-changer for the Big Apple and a potential blueprint…
PR mega-merger threatens the very soul of creativity
By DAVID A. CHAUVIN // In one memorable episode of “Mad Men,” Sterling Cooper merges into the tongue-twisting Sterling Cooper Draper Pryce, igniting a chaotic clash of egos and overlapping…
Feds scuffle as minorities pay a heavy diabetes price
By JEFFREY L. REYNOLDS // André “Doctor Dre” Brown can’t prescribe Ozempic because he’s not that kind of doctor, but that hasn’t stopped the Beastie Boys DJ and 1990s co-host…
With billions in play, opioid settlements turn political
By TERRY LYNAM // To those who’ve lost a loved one, it’s blood money: $55 billion in court settlements to be paid out in response to the 900,000 American lives…